Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIOLIFE SOLUTIONS INC Director's Dealing 2019

Nov 9, 2019

32106_dirs_2019-11-08_14de8166-937e-40f3-a403-11a734cbec2d.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOLIFE SOLUTIONS INC (BLFS)
CIK: 0000834365
Period of Report: 2019-11-06

Reporting Person: DE GREEF RODERICK (Chief Financial Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2019-11-06 Common Stock M 10000 $1.64 Acquired 35859 Direct
2019-11-06 Common Stock S 10000 $17.81 Disposed 25859 Direct
2019-11-07 Common Stock M 10000 $1.76 Acquired 35859 Direct
2019-11-07 Common Stock S 10000 $17.08 Disposed 25859 Direct
2019-11-08 Common Stock M 10000 $1.76 Acquired 35859 Direct
2019-11-08 Common Stock S 10000 $16.44 Disposed 25859 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2019-11-06 Employee Stock Option $1.64 M 10000 Disposed 2021-12-20 Common Stock (10000) Direct
2019-11-07 Employee Stock Option $1.76 M 10000 Disposed 2026-03-04 Common Stock (10000) Direct
2019-11-08 Employee Stock Option $1.76 M 10000 Disposed 2026-03-04 Common Stock (10000) Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Employee Stock Option $1.8099 2026-05-03 Common Stock (104000) 104000 Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2018.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.16 to $18.65 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.90 to $17.61 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.20 to $16.60 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F5: The stock option vests 25% on the first anniversary of the grant date and thereafter, in 36 equal monthly installments. Such options shall continue to vest regardless of whether Mr. de Greef's service with the Company continues

F6: The stock option vests 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter.